Catching the Next Swiss Wave of Innovation in Immunology – with Johnson & Johnson

Advanced medicines for immune-mediated diseases have benefited millions of people worldwide, but the reality is that treatment for many millions more is still lacking. New discoveries into immune system function are leading to profound learnings about drivers of disease, encouraging exploration of mechanisms that move beyond immunosuppression and toward restoring homeostasis. As a result of these findings, a significant portion of new therapeutics being developed for chronic conditions in 2022 targeted immunological disorders and are forecasted to drive key growth in specialty pharmacy over the coming years, with global spending expected to reach $158.7 billion by 2028.

Join Johnson & Johnson’s external scientific innovation team on May 21 in Basel for an engaging dialogue with global and regional experts to explore this next generation of advanced therapies and platforms in key J&J areas of interest such as rheumatology (RA, PsA, AxSpa), gastroenterology (CD, UC), immunodermatology (PsO, AD, HS), as well as autoantibody, maternal-fetal and respiratory conditions (asthma, COPD).

The discussion during the event will focus on next generation innovations including:

• targeted immune cell depletion
• first in class orals targeted against proven pathways
• immune cell counter regulation
• barrier and pro-resolving targets
• inflammatory fibrosis
• platforms and technologies for precision medicine approaches and non-invasive measurement of disease

During this event, organized in collaboration with BaseLaunch, you will also learn how Johnson & Johnson harnesses deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and start-up services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists and emerging companies.

1:1 Meetings
Early-stage companies and researchers are welcome to request to meet J&J team in person if they apply by 7 May EOD. Organizations with a portfolio of start-ups, such as VCs, TTOs or incubators are also encouraged to apply.
Apply here